Peptide Dosages and Titration Guide: Common Doses, Research Protocols, and Community-Reported Schedules
Peptide dosing can be confusing because the term peptide covers everything from fully FDA-approved prescription medications to experimental research compounds that have never completed a human dose-finding study.
For that reason, this guide uses three different classifications:
FDA-approved dosing means the schedule comes from current pharmaceutical prescribing information.
Clinical/research peptide dosages means the amount has been used in published human studies but is not necessarily an approved treatment regimen.
Community-reported dosing refers to commonly cited schedules published by peptide-reference sources such as PeptideDeck, The Peptide Catalog, and DosagePeptide. These schedules describe how experimental compounds are commonly discussed or used in research-oriented communities. They are not FDA-approved dosing recommendations and should not be interpreted as medical advice.
Peptide Quick Navigation
- Semaglutide
- Tirzepatide
- Retatrutide
- Cagrilintide
- Tesamorelin
- Sermorelin
- Ipamorelin
- CJC-1295 Without DAC
- CJC-1295 With DAC
- CJC-1295 + Ipamorelin
- Tesamorelin + Ipamorelin
- BPC-157
- TB-500
- BPC-157 + TB-500
- GHK-Cu
- KPV
- GLOW and KLOW
- AOD-9604
- 5-Amino-1MQ
- MOTS-c
- SS-31 / Elamipretide
- IGF-1 LR3
- Epithalon / Epitalon
- Semax
- Selank
- Semax + Selank
- Pinealon
- DSIP
- Melanotan II
- PT-141 / Bremh-
- elanotide
- Thymosin Alpha-1
- Kisspeptin
- Oxytocin
- VIP / Aviptadil
- Glutathione
- NAD+
- SNAP-8
- Bacteriostatic Water
Semaglutide
Status: FDA-approved
Semaglutide is a GLP-1 receptor agonist used in several FDA-approved products, including Wegovy and Ozempic.
For injectable Wegovy, the standard titration progresses gradually:
Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onward: generally 2.4 mg once weekly.
The slow titration is primarily intended to reduce gastrointestinal side effects such as nausea and vomiting.
Ozempic likewise begins at 0.25 mg weekly for four weeks, usually progressing to 0.5 mg and, when additional glycemic control is needed, 1 mg or 2 mg weekly.
Tirzepatide
Status: FDA-approved
Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound.
The typical escalation is:
Weeks 1–4: 2.5 mg once weekly
Week 5 onward: 5 mg once weekly.
If further effect is required and the medication is tolerated, the dose can generally increase by 2.5 mg increments after at least four weeks at the previous dose.
Common dose levels are:
2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly.
The maximum commonly labeled dose is 15 mg once weekly.
Retatrutide
Status: Investigational
Retatrutide activates:
GLP-1 + GIP + glucagon receptors.
It remains an investigational medication as of 2026.
Clinical trials have evaluated several once-weekly dose levels with gradual escalation to improve gastrointestinal tolerability.
There is currently no FDA-approved starting, maintenance, or maximum dose.
Any schedule offered outside an authorized clinical trial should therefore be described as experimental rather than established medical dosing.
Cagrilintide
Status: Investigational
Cagrilintide is a long-acting amylin analogue being developed for obesity, including in combination with semaglutide.
Importantly, cagrilintide actually has a formal clinical-trial titration schedule despite not yet being FDA approved.
PeptideDeck summarizes the Phase 3 trial progression as:
Weeks 1–4: 0.25 mg weekly
Weeks 5–8: 0.5 mg weekly
Weeks 9–12: 1.0 mg weekly
Weeks 13–16: 1.7 mg weekly
Week 17 onward: 2.4 mg weekly.
Each step is generally held for four weeks.
The Peptide Catalog also distinguishes the 2.4 mg weekly clinical-trial dose from much smaller community protocols sometimes discussed online.
For an educational article, the clinical trial schedule is the more scientifically meaningful reference.
Tesamorelin
Status: FDA-approved
Tesamorelin is a GHRH analogue marketed as EGRIFTA WR for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
The current approved regimen is:
1.28 mg subcutaneously once daily.
Tesamorelin does not normally require a dose-escalation phase.
Older references often list 2 mg daily because earlier EGRIFTA formulations had different bioavailability.
The newer 1.28 mg EGRIFTA WR regimen should not be compared milligram-for-milligram with those older formulations.
Sermorelin
Status: Historically FDA-approved; currently generally compounded/research use
Sermorelin is GHRH(1-29).
Historical pediatric studies used approximately:
30 mcg/kg once daily, commonly administered at bedtime.
That was a pediatric growth-hormone-deficiency protocol rather than a modern adult wellness schedule.
Contemporary fixed-dose adult protocols promoted by peptide clinics vary substantially and do not represent a current FDA-approved regimen.
Therefore, sermorelin is best described as having historical clinical dosing but no currently standardized FDA-approved adult titration schedule.
Ipamorelin
Status: Unapproved research peptide
Ipamorelin stimulates growth hormone through the ghrelin/GHS-R1a receptor.
No FDA-approved regimen exists.
PeptideDeck describes community injectable schedules beginning around:
100 mcg once daily, often before bedtime,
with a commonly reported standard amount around:
200 mcg per administration.
These numbers are important to characterize correctly.
PeptideDeck itself notes that no published human trial has established a subcutaneous Ipamorelin dosing regimen.
Therefore, the 100–200 mcg range is a community convention, not a medically established therapeutic dose.
CJC-1295 Without DAC
Status: Unapproved research peptide
CJC-1295 without DAC—often associated with Modified GRF(1-29)—is relatively short acting.
PeptideDeck reports community protocols of approximately:
100–200 mcg per administration
given roughly:
2–3 times daily.
A frequently referenced combination pairs similar amounts of CJC-1295 without DAC and Ipamorelin.
PeptideDeck also explicitly identifies these schedules as research/community dosing rather than FDA-approved treatment.
There is no medically validated CJC-1295 without DAC titration schedule.
CJC-1295 With DAC
Status: Unapproved research peptide
CJC-1295 with DAC is designed for much longer action because the Drug Affinity Complex allows prolonged albumin binding.
PeptideDeck documents commonly discussed schedules around:
1–2 mg per week.
Some community approaches administer the total once weekly, while others divide the weekly amount.
Because of its prolonged half-life, CJC-1295 with DAC should not be confused with short-acting CJC without DAC.
Again, this represents community convention rather than an FDA-approved dosing schedule.
CJC-1295 + Ipamorelin
Status: Unapproved combination
One of the most common GH-secretagogue combinations uses:
CJC-1295 without DAC + Ipamorelin.
PeptideDeck describes a commonly cited 1:1 community pairing around:
100 mcg CJC-1295 + 100 mcg Ipamorelin per administration
with protocols often repeated multiple times per day.
The same source describes a conservative progression beginning with CJC alone before adding Ipamorelin.
There is no FDA-approved combination, ratio, dose, or titration schedule.
Tesamorelin + Ipamorelin
Status: Unapproved combination
Tesamorelin itself has an FDA-approved regimen, but combining it with Ipamorelin creates an entirely different treatment.
There are currently no controlled human trials establishing:
the ideal ratio
the ideal Ipamorelin amount
or whether adding Ipamorelin improves tesamorelin’s visceral-fat benefit.
Accordingly, there is no scientifically established titration schedule for the combination.
The approved 1.28 mg/day EGRIFTA WR regimen applies only to tesamorelin monotherapy for its labeled indication.
BPC-157
Status: Unapproved research peptide
BPC-157 is probably one of the clearest examples of a widely repeated community dose that is not based on formal human dose-finding research.
PeptideDeck reports:
Conservative: approximately 250 mcg once daily
Common community schedule: approximately 250 mcg twice daily
Higher short-term community schedule: approximately 500 mcg twice daily.
Typical cycles are described as roughly 4–6 weeks.
Crucially, PeptideDeck acknowledges that these doses are community conventions and that no established human injectable dose-response study exists.
There is no FDA-approved BPC-157 dose, loading phase, maintenance schedule, or injury-treatment regimen.
TB-500
Status: Unapproved research peptide
PeptideDeck documents one of the most commonly repeated TB-500 community schedules as:
Loading Phase
Approximately:
2–2.5 mg twice weekly
for:
4–6 weeks.
Community Maintenance Phase
Approximately:
2–2.5 mg once weekly.
PeptideDeck describes roughly 4–5 mg/week during loading as the range most vendor and community schedules converge on.
The same source is unusually clear about the limitation:
no published human dosing study of the TB-500 fragment has established these amounts.
Therefore, the familiar “loading and maintenance” structure is a community convention, not a medically accepted regimen.
BPC-157 + TB-500
Status: Unapproved research combination
Community protocols frequently combine the standard individual schedules:
BPC-157 around:
250 mcg once or twice daily
with TB-500 around:
2–2.5 mg twice weekly during a loading period.
However, no FDA-approved ratio exists.
Furthermore, a 2026 animal study directly evaluating BPC-157 and TB-500 found that combining the two did not clearly outperform the individual compounds.
Consequently, there is no evidence-based reason to assume that a combination schedule is superior simply because it is popular.
GHK-Cu
Status: Topically established; injectable use remains experimental
GHK-Cu has a meaningful history of topical cosmetic use.
Injectable dosing is much less established.
The Peptide Catalog reports a community injectable protocol around:
1.7 mg daily
with cycles around:
8 weeks on followed by 8 weeks off.
Importantly, that same source states:
injectable GHK-Cu has no human clinical dosing trials.
Therefore, the 1.7 mg/day figure should be presented only as a community-reported research convention.
Topical GHK-Cu should be treated separately because topical concentrations and systemic injectable doses are not equivalent.
KPV
Status: Unapproved research peptide
KPV is a three-amino-acid fragment associated primarily with anti-inflammatory and gastrointestinal research.
PeptideDeck reports:
Conservative: approximately 250 mcg daily
Common community schedule: approximately 500 mcg daily.
Some community sources describe twice-daily administration during short periods, but there is no human dose-finding trial supporting this practice.
PeptideDeck explicitly notes that the commonly referenced 500 mcg/day injectable amount is a compounding/community convention rather than a trial-derived human dose.
Interestingly, much of the original laboratory research involved oral exposure, not subcutaneous dosing.
GLOW and KLOW
Status: Unapproved research blends
GLOW generally refers to combinations containing:
GHK-Cu + BPC-157 + TB-500.
KLOW generally adds:
KPV.
There is no standardized pharmaceutical definition of either blend.
Because individual manufacturers may use different ratios, there is no universal:
dose
titration
loading phase
or maintenance schedule.
Any GLOW or KLOW protocol should therefore identify the exact quantities of each ingredient rather than discussing the blend as though it were a standardized drug.
AOD-9604
Status: Investigational
AOD-9604 is a modified growth-hormone fragment that underwent clinical research for obesity but was never approved as a weight-loss medication.
The Peptide Catalog documents common research-community schedules around:
250–500 mcg daily, with approximately 300 mcg/day appearing frequently in community protocols.
The same source describes common cycling conventions around:
5 days on / 2 days off
for approximately:
8 weeks, followed by a break.
DosagePeptide likewise emphasizes that such charts are research modeling rather than instructions for human administration.
There is no FDA-approved modern AOD-9604 dosing regimen.
5-Amino-1MQ
Status: Experimental small molecule; technically not a peptide
5-Amino-1MQ is an NNMT inhibitor commonly sold alongside peptides.
The Peptide Catalog documents community oral protocols of approximately:
50 mg/day initially
followed by commonly discussed amounts around:
100–150 mg/day.
Cycles of approximately:
8–12 weeks
are often reported.
This source explicitly states that no human clinical trials have established dosing.
Therefore these figures are community-derived rather than medically validated.
MOTS-c
Status: Investigational mitochondrial-derived peptide
MOTS-c is being studied for metabolic and mitochondrial signaling.
DosagePeptide reports that a frequently repeated community figure is approximately:
200 mcg daily
often used around:
5 days per week.
More importantly, DosagePeptide explicitly says this figure is a convention rather than a finding from a human dose-ranging trial.
Formal human clinical development has now begun, but there is still no FDA-approved MOTS-c dosage.
SS-31 / Elamipretide
Status: FDA-approved for a specific rare disease
Elamipretide, formerly known as SS-31, is marketed as Forzinity.
For qualifying patients with Barth syndrome weighing at least 30 kg, the approved regimen is:
40 mg subcutaneously once daily.
There is no titration sequence for the standard labeled dose.
This 40 mg amount applies to Barth syndrome, not general mitochondrial optimization, anti-aging, exercise performance, or fatigue.
IGF-1 LR3
Status: Unapproved research analogue
IGF-1 LR3 is a modified analogue of IGF-1.
PeptideDeck reports community schedules commonly centered around:
20–40 mcg once daily
for approximately:
4–6 weeks, commonly followed by an equivalent break.
PeptideDeck explicitly notes:
no human clinical dosing study of IGF-1 LR3 has been published.
Because IGF signaling affects glucose metabolism, the absence of human safety data is particularly important.
IGF-1 LR3 should also not be confused with FDA-approved mecasermin, which is a different pharmaceutical compound.
Epithalon / Epitalon
Status: Unapproved research peptide
Epithalon is usually discussed in terms of short “cycles” rather than continuous use.
PeptideDeck reports common community conventions of:
5–10 mg daily
for approximately:
10–20 days,
often repeated:
once or twice yearly.
However, PeptideDeck also points out that the published systemic human dose historically reported was much lower—around 0.5 mg daily for 20 days—and that the larger 5–10 mg regimens are largely vendor/community convention.
There is no FDA-approved anti-aging or longevity dose.
Semax
Status: Unapproved in the United States
Semax has been used intranasally in Russian neurological research.
For contemporary research-community use, PeptideDeck describes:
Conservative: approximately 100–200 mcg daily
Common range: roughly 200–300 mcg once or twice daily
Upper community range: approximately 300–600 mcg once or twice daily.
Typical community cycles are around:
2–4 weeks.
Another PeptideDeck reference condenses the usual community daily range to approximately:
200–600 mcg/day, often around 300 mcg/day.
Critically, the source acknowledges that these smaller nootropic schedules are community conventions and that published human trials generally involved intranasal administration and very different disease-specific doses.
Selank
Status: Unapproved in the United States
Selank has been investigated primarily for anxiety and stress-related effects.
PeptideDeck describes common community protocols such as:
250 mcg once daily initially
and:
250–500 mcg once or twice daily
for approximately:
2–4 weeks.
A separate dosing chart lists:
250–500 mcg/day as the commonly used subcutaneous community range, while emphasizing that human anxiolytic trials used intranasal rather than injectable administration.
That route distinction is important.
There is no FDA-approved Selank dose.
Semax + Selank
Status: Unapproved combination
Community discussions often pair comparable low-microgram quantities of each compound.
A typical conceptual approach is:
Semax in the morning for cognitive activation
plus:
Selank for anxiety/stress modulation.
There is no validated:
1:1 ratio
titration schedule
or controlled human combination protocol.
Consequently, the individual community ranges described above should not be interpreted as evidence that they should simply be added together.
Pinealon
Status: Unapproved peptide bioregulator
Pinealon is a short Glu-Asp-Arg tripeptide.
PeptideDeck describes a Russian-style oral product using approximately:
10 mg per capsule, commonly taken through short courses.
Another PeptideDeck summary describes community schedules such as:
Oral: roughly 20 mg/day for 20–30 days
Injectable community protocol: roughly 5–10 mg/day for 10–20 days.
These cycles are sometimes repeated a few times annually.
However, PeptideDeck explicitly characterizes these as derived from Russian/commercial protocols rather than internationally validated clinical dosing.
DSIP
Status: Experimental
Delta Sleep-Inducing Peptide has been researched for sleep and neurological applications.
There is no FDA-approved DSIP regimen.
Community protocols vary substantially, which itself reflects the absence of a validated dose-response relationship.
Any specific DSIP amount circulated online should therefore be described as experimental rather than generally accepted dosing.
Melanotan II
Status: Unapproved
Melanotan II is an experimental melanocortin agonist.
PeptideDeck describes the common community approach as:
Test Amount
Approximately:
100 mcg once
to assess tolerance.
Community Loading Phase
Approximately:
250 mcg once daily
for roughly:
1–3 weeks, stopping when the desired pigmentation is reached.
Community Maintenance
Approximately:
250 mcg once or twice weekly.
PeptideDeck explicitly states that these are community/vendor conventions rather than regulator-reviewed dosing.
Melanotan II is not FDA approved, and significant safety concerns include nausea, mole pigmentation, priapism, and uncertainty regarding long-term melanocyte effects.
PT-141 / Bremelanotide
Status: FDA-approved for a specific indication
Bremelanotide is marketed as Vyleesi for acquired, generalized hypoactive sexual desire disorder in qualifying premenopausal women.
The FDA-approved regimen is:
1.75 mg subcutaneously as needed
at least:
45 minutes before anticipated sexual activity.
The label limits use to:
no more than once every 24 hours
and generally:
no more than eight doses per month.
PeptideDeck’s dosing reference reflects the same 1.75 mg labeled dose.
Lower “test” doses and nasal protocols discussed online are not part of the FDA-approved schedule.
Thymosin Alpha-1
Status: International pharmaceutical use; not FDA-approved in the United States
Thymosin Alpha-1 is marketed internationally as thymalfasin/Zadaxin.
PeptideDeck summarizes the widely used international pharmaceutical protocol as:
1.6 mg subcutaneously twice weekly
with doses separated by approximately:
3–4 days.
Disease-specific treatment duration varies.
Some historical treatment programs used several months of therapy.
The 1.6 mg twice-weekly figure has much stronger human evidence than most community research-peptide doses, but it is not an FDA-approved U.S. regimen.
Kisspeptin
Status: Investigational reproductive peptide
Kisspeptin dosing varies dramatically according to:
kisspeptin-10 versus kisspeptin-54
sex
fertility status
and the purpose of the study.
Clinical fertility studies have used carefully controlled weight-based doses to trigger egg maturation.
Because the dosing is highly indication-specific, there is no meaningful general consumer kisspeptin dose or titration schedule.
This is a compound for which study-specific dosing is considerably more meaningful than an online “standard dose.”
Oxytocin
Status: FDA-approved for obstetric uses
Oxytocin has well-established hospital dosing.
For labor induction, IV infusion may begin around:
1–2 milliunits per minute
and is gradually increased according to uterine activity and fetal response.
This is true medical titration performed under continuous monitoring.
Postpartum protocols use different IV or IM doses.
Intranasal oxytocin used experimentally for:
social behavior
autism
sexual function
or appetite
does not have an FDA-approved general dosing schedule.
VIP / Aviptadil
Status: Investigational
Vasoactive Intestinal Peptide has been studied by:
inhalation
IV administration
and other experimental routes.
For example, pulmonary hypertension research has evaluated inhaled doses around:
100 mcg of aviptadil.
That number represents a clinical experiment rather than a consumer dosing protocol.
Because VIP can affect:
blood pressure
heart rate
bronchial tone
and intestinal secretion,
there is no broadly accepted wellness or anti-aging schedule.
Glutathione
Status: Naturally occurring tripeptide; oral supplements widely available
Oral glutathione studies have commonly used:
250 mg/day
through approximately:
1,000 mg/day.
A six-month randomized trial investigated both 250 mg and 1,000 mg daily and demonstrated increases in body glutathione stores.
These oral amounts should not be converted into IV dosing.
There is no FDA-approved intravenous glutathione regimen for:
anti-aging
detoxification
or skin lightening.
NAD+
Status: Naturally occurring coenzyme; not actually a peptide
NAD+ is frequently grouped with peptide therapies.
Commercial wellness clinics use widely varying intravenous amounts, but there is no FDA-approved IV NAD+ anti-aging or wellness dosing schedule.
This variation itself is a useful warning that there is no universally established regimen.
Research on oral precursors such as:
NR
and NMN
is considerably more developed than evidence supporting standardized IV NAD+ protocols.
SNAP-8
Status: Topical cosmetic peptide
SNAP-8, or Acetyl Octapeptide-3, is primarily intended for topical cosmetic use.
It has no established:
injectable dose
systemic dose
or medical titration schedule.
Cosmetic products use varying concentrations, and percentages may refer to diluted raw-material preparations rather than pure peptide concentration.
SNAP-8 should therefore be discussed as a formulation ingredient rather than a systemically dosed peptide.
Bacteriostatic Water
Status: Pharmaceutical diluent; not a peptide
Bacteriostatic Water for Injection commonly contains:
0.9% benzyl alcohol.
It does not have a therapeutic “dose.”
The amount used depends on the drug manufacturer’s validated reconstitution instructions.
Adding different amounts of bacteriostatic water changes the concentration of the final solution, not the amount of active ingredient contained in the vial.
There is no universal rule that all peptides should be reconstituted with 1 mL, 2 mL, or any other fixed volume.
Quick Classification: Which Peptides Actually Have Established Dosing?
The simplest way to interpret peptide dosing is to separate the compounds into groups.
FDA-Approved or Formally Established Pharmaceutical Dosing
Semaglutide
Tirzepatide
Tesamorelin
PT-141/Bremelanotide
Oxytocin
SS-31/Elamipretide
These have regulator-reviewed dosing for specific indications.
Investigational Compounds With Formal Human Trial Dosing
Retatrutide
Cagrilintide
Kisspeptin
These have meaningful clinical-study schedules, but those schedules do not yet constitute general FDA-approved treatment.
Historical or International Clinical Dosing
Sermorelin
Thymosin Alpha-1
Semax
Selank
Pinealon
Human use exists, but the regulatory and evidence base differs considerably from currently FDA-approved U.S. medicines.
Community/Research Protocols Rather Than Established Medical Dosing
BPC-157
TB-500
BPC-157 + TB-500
Ipamorelin
CJC-1295
CJC-1295 + Ipamorelin
Tesamorelin + Ipamorelin
MOTS-c
IGF-1 LR3
KPV
GHK-Cu injection
Epithalon
Melanotan II
AOD-9604
5-Amino-1MQ
GLOW/KLOW
For these compounds, commonly quoted numbers largely represent community, vendor, clinic, or research-market convention rather than validated medical dosing.
Why the Distinction Matters
There is a major difference between:
“This is the dose used in an FDA-reviewed Phase 3 program”
and:
“This is the amount most peptide websites say people use.”
Both pieces of information can be useful in an educational reference.
They are not equivalent.
PeptideDeck itself repeatedly acknowledges this distinction. Its BPC-157 page states that the commonly repeated dosing comes from convention rather than human injectable trials. Its TB-500 page similarly states that no human TB-500 dosing study has established the familiar loading schedule. DosagePeptide makes the same point about its frequently repeated MOTS-c number.
That transparency is important.
A community protocol can tell researchers:
what is commonly discussed
or:
what dosage range is circulating in the marketplace.
It cannot prove that the amount is:
safe
effective
optimal
or even biologically appropriate.
Final Thoughts
Peptide dosing ranges from extremely well established to almost completely speculative.
At one end of the spectrum, drugs such as semaglutide and tirzepatide have been administered to tens of thousands of people through tightly controlled clinical programs.
At the other end are compounds such as TB-500, IGF-1 LR3, KPV, and MOTS-c, where commonly quoted human schedules have largely developed through research suppliers, peptide clinics, online communities, and extrapolation rather than controlled human dose-finding trials.
For educational purposes, it can still be useful to know what those commonly cited schedules are.
The critical step is labeling them correctly.
A phrase such as:
“commonly reported research/community protocol”
is appropriate.
Calling the same number:
“the recommended human dose”
often is not.
As peptide research matures, some of today’s community protocols may eventually be replaced by genuine Phase 1 dose-ranging studies, Phase 2 efficacy trials, and Phase 3 treatment regimens.
Until then, the source and strength of the evidence matter just as much as the number itself.
Medical Disclaimer
This article is provided solely for educational, informational, and research-reference purposes. It is not medical advice, prescribing guidance, or a recommendation to purchase, prepare, inject, ingest, compound, or otherwise use any peptide, medication, supplement, or research compound.
FDA-approved doses discussed in this article summarize general prescribing information for specific products and indications. They may not be appropriate for every individual. Medication selection, titration, dose changes, monitoring, and discontinuation should be determined by a qualified healthcare professional using the patient’s complete medical history, laboratory results, other medications, contraindications, and treatment goals.
Research Peptide Disclaimer
Many compounds discussed in this article—including BPC-157, TB-500, CJC-1295, Ipamorelin, MOTS-c, IGF-1 LR3, KPV, Epithalon, Melanotan II, and numerous peptide blends—are not FDA-approved for human use. The community dosing ranges attributed to PeptideDeck, The Peptide Catalog, DosagePeptide, peptide clinics, research communities, or similar sources describe reported conventions and should not be interpreted as medically validated dosing recommendations.
Commercial peptide-information websites are secondary sources and may contain opinions, extrapolations, vendor conventions, self-reported practices, or interpretations that have not been confirmed in controlled clinical trials. Their inclusion in this article documents commonly reported dosing practices; it does not constitute endorsement of those practices.
Product Quality Disclaimer
Research-grade and compounded products should not be assumed equivalent to FDA-approved pharmaceutical products. Differences may exist in chemical identity, purity, potency, sterility, endotoxin levels, concentration, stability, storage requirements, and manufacturing controls. The use of sterile bacteriostatic water does not convert a nonsterile or research-grade compound into a pharmaceutical-grade injectable product.
Safety Disclaimer
Peptides can affect major physiological systems including glucose regulation, blood pressure, heart rate, growth hormone and IGF-1 signaling, reproductive hormones, immune function, gastrointestinal motility, pigmentation, and neurological function. Some compounds may interact with medications or medical conditions in potentially serious ways. Anyone considering treatment involving a peptide or peptide-based medication should consult an appropriately licensed healthcare professional and follow current official prescribing information where an approved product exists.
